Market Overview

Choroidal Neovascularization | A Drug Pipeline Analysis Report 2018 | Technavio

Share:

Technavio has announced their latest pipeline analysis report on the
drug pipeline for choroidal
neovascularization
. The report includes a detailed analysis of
the pipeline molecules under investigation within the defined data
collection period to treat choroidal neovascularization.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180813005248/en/

Technavio has published a new report on the drug development pipeline for choroidal neovascularizati ...

Technavio has published a new report on the drug development pipeline for choroidal neovascularization, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market.

This report is available at a USD 1,000 discount for a limited time
only:
View
market snapshot before purchasing

Choroidal neovascularization: Market overview

Choroidal neovascularization is the creation of new blood vessels in the
choroid layer of the eye. It is a common cause of neovascular
degenerative maculopathy, which is also known as wet macular
degeneration. Extreme myopia, malignant myopic degeneration, or
age-related developments commonly exacerbate choroidal
neovascularization.

According to a senior market research analyst at Technavio, "Choroidal
neovascularization can be detected by using a type of perimetry called
preferential hyperacuity perimetry. Based on fluorescein angiography,
the choroidal neovascularization may be described as classic or occult.
Two other tests that help identify the condition include indocyanine
green angiography and optical coherence tomography."

Choroidal neovascularization: Segmentation
analysis

This pipeline analysis report segments the choroidal neovascularization
market based on therapies employed (monotherapy and
monotherapy/combination therapy), RoA (intravitreal), therapeutic
modality (monoclonal antibody, recombinant fusion protein,
oligonucleotide, recombinant protein and small molecule), targets
(tissue factor, VEGF-A, TK, VEGF-A and ANG-2, TGF- β, and VEGF-A and
PIGF), MoA (angiogenesis inhibitor, VEGF-A inhibitor, TK inhibitor,
VEGF-A and ANG-2 inhibitor, TGF- β inhibitor, and VEGF-A and PIGF
inhibitor), geographical segmentation (US), and recruitment status
(completed and recruiting). It provides an in-depth analysis of the
prominent factors influencing the market, including drivers,
opportunities, trends, and industry-specific challenges.

Based on therapeutic modality, around 29% of the molecules that are
being investigated for the treatment of choroidal neovascularization are
monoclonal antibodies.

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

View Comments and Join the Discussion!